Why IDEXX Laboratories Stock Looks Undervalued After Raising Its 2026 EPS Outlook to $15

Key Takeaways for IDEXX Laboratories Stock as of June 2026

• Analysts rate IDEXX Laboratories stock 5 Buys, 4 Outperforms, 5 Holds, 1 Underperform, and 1 Sell, with a street mean target of $709, implying around 29% upside from the current price of $549.
• TIKR’s mid-case model values IDEXX at around $862 by December 2030, implying around 57% total return from current levels, or roughly 11% annualized.
• IDEXX Laboratories stock is undervalued at current levels, with normalized EPS of $3.47 in Q1 2026 already tracking well ahead of year-ago comparisons and a raised full-year guidance range of $14.45 to $14.90 validating the earnings growth trajectory.
• IDEXX placed 1,100 inVue Dx analyzers in Q1 2026 and confirmed it remains comfortably within its $3,500 to $5,500 annual revenue-per-instrument band even before a full fine needle aspirate launch, pointing to further consumables expansion in the second half.

The IDEXX beat-and-raise cycle is running. Explore IDXX financials and analyst estimates on TIKR for free →

IDEXX Stock Beats Q1 Estimates and Raises Guidance on Accelerating Diagnostics Demand

IDEXX Laboratories (IDXX), the global leader in veterinary diagnostics and software, delivered a Q1 2026 revenue beat and raised its full-year guidance on May 5, driven by 14.26% year-over-year revenue growth to $1,140.82 million against a street estimate of $1,108.83 million.

Adjusted EPS came in at $3.47, up 17.23% year over year, ahead of the $3.41 consensus.

The Companion Animal Group (CAG), which is IDEXX’s largest revenue segment and covers in-clinic diagnostic instruments, reference lab testing, and veterinary software, grew 15% to $1.05 billion in the quarter.

CAG Diagnostics recurring revenue, the most watched growth metric for the segment because it captures ongoing consumables and reference lab volume rather than one-time instrument sales, rose 14% on a reported basis and 11% organically.

International CAG Diagnostics recurring revenue grew 12% organically, while the U.S. segment expanded nearly 11%, both outpacing the minus 1% same-store clinical visit decline for the period.

CEO Jay Mazelsky, in his final earnings call before transitioning to Executive Chair, attributed the outperformance to something structural rather than cyclical: “IDEXX delivered an exceptional start to 2026 with first quarter results reflecting disciplined commercial execution, continued benefits from innovation and expanded diagnostics utilization across our global customer base.”

The company placed 1,100 IDEXX inVue Dx analyzers in Q1, an AI-powered cytology instrument that automates ear, blood morphology, and fine needle aspirate analysis directly at the point of care, tracking toward the full-year target of 5,500 placements.

Incoming CEO Mike Erickson also confirmed at the Stifel Jaws and Paws Conference in May that inVue Dx already sits within the $3,500 to $5,500 revenue-per-instrument annual band even before the fine needle aspirate application reaches full launch later in 2026.

IDEXX also continued expanding IDEXX Cancer Dx, its liquid biopsy test for early canine cancer detection, which now has over 7,500 practices ordering since launch, with 70% of volume bundled alongside blood panels at IDEXX reference labs.

Full-year guidance moved higher: IDEXX raised its 2026 revenue range to $4.675 billion to $4.760 billion and lifted its EPS outlook to $14.45 to $14.90.

The story developing inside IDXX is harder to see from the headline numbers alone. Track IDEXX Laboratories stock earnings revisions and estimate trajectory on TIKR for free →

Analysts Hold Buy Ratings on IDXX Stock as EPS Growth Trajectory Holds Through Macro Noise

Wall Street expects IDEXX Laboratories stock to deliver around 9% EPS growth in the quarter ending June 2026, with normalized EPS consensus at $3.94 against the $3.47 reported in Q1, and 14 of 15 covering analysts hold a Buy, Outperform, or Hold rating with a mean target of $709.

The Q1 result confirms the growth engine is running, with IDEXX reporting normalized EPS of $3.47 in the March quarter, up from $3.08 in December 2025 and $2.96 in March 2025, a 17% year-over-year gain that beat the $3.41 street estimate by 1.74%.

Accordingly, forward consensus extends that momentum, with analysts estimating normalized EPS of $3.94 in Q2 2026, $3.78 in Q3, and $3.45 in Q4, implying full-year 2026 EPS of around $14 at the street midpoint, consistent with IDEXX’s own raised guidance of $14.45 to $14.90.

The 2027 estimates carry the trajectory further, with consensus at $3.89 for Q1 2027 and $4.42 for Q2 2027, implying around 12% normalized EPS growth year over year in each of those periods.

Instrument economics compounding at scale drives that conviction, and as the inVue Dx installed base grows and fine needle aspirate rolls out fully in the second half, consumable revenue per instrument rises, building a recurring revenue floor that is largely visit-independent.

Meanwhile, IDEXX’s free cash flow of $234.26 million in Q1 2026 beat the $232.00 million consensus, and management maintained its full-year FCF conversion guidance of 85% to 95% of net income while deploying $361 million in share repurchases during the quarter alone.

The 9 Buy and Outperform ratings against 5 Holds reflect a concrete disagreement: bulls treat inVue Dx and Cancer Dx as multi-year compounding platforms that will sustain double-digit EPS growth regardless of visit volume headwinds, while the Hold camp wants to see full-year FNA utilization data before upgrading conviction ahead of a minus 1.5% clinical visit assumption for the full year.

IDXX vs ZTS and ELAN: The Normalized Earnings Gap Only Widens From Here

IDEXX Laboratories stock posted $13.08 billion in normalized earnings in fiscal 2025, against $6.34 billion for Zoetis (ZTS) and $0.94 billion for Elanco Animal Health (ELAN), a premium that reflects IDEXX’s diagnostics-led recurring revenue model rather than the broader pharmaceutical exposure carried by its peers.

By fiscal 2030, estimates put IDEXX at around $24 billion, Zoetis at around $9 billion, and Elanco at around $2 billion, a ratio that widens rather than compresses across the full forecast window.

Is IDEXX Stock Undervalued in 2026? TIKR’s $862 Mid-Case Says Yes

TIKR’s mid-case model values IDEXX Laboratories at around $862 by December 2030, implying around 57% total return from the current price of $549, or roughly 11% annualized over 4.5 years.

IDEXX Laboratories stock’s EPS trajectory is the load-bearing assumption, and the Q1 beat, the raised guidance, and forward consensus pointing to around 12% annual EPS growth through 2027 each confirm the earnings compounding profile the target requires.

The inVue Dx installed base, already comfortably inside the $3,500 to $5,500 annual revenue-per-instrument band before fine needle aspirate reaches full volume, adds a layer of recurring revenue growth that becomes a structural EPS tailwind as the 5,500-unit 2026 placement target completes.

The target holds as long as CAG Diagnostics recurring revenue sustains organic growth in the high single digits, the condition IDEXX has now met across multiple quarters and explicitly defended at both the earnings call and the May investor conference.

The TIKR model puts IDEXX stock at around $862 by 2030. See every assumption driving that figure on TIKR for free →

Should You Invest in IDEXX Laboratories, Inc.?

The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.

Pull up IDEXX Laboratories, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.

You can build a free watchlist to track IDEXX Laboratories, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.

Access Professional Tools to Analyze IDXX stock on TIKR for Free →